Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) was the target of some unusual options trading activity on Wednesday. Stock investors bought 7,222 call options on the stock. This represents an increase of approximately 6,778% compared to the typical volume of 105 call options.
Separately, B. Riley assumed coverage on shares of Checkpoint Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $18.00 target price for the company.
Shares of CKPT opened at $3.03 on Friday. The business’s fifty day simple moving average is $2.74. Checkpoint Therapeutics has a 12 month low of $1.56 and a 12 month high of $5.38. The firm has a market cap of $239.93 million, a price-to-earnings ratio of -6.89 and a beta of 1.53.
Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in Checkpoint Therapeutics by 9.4% in the 1st quarter. BlackRock Inc. now owns 3,544,060 shares of the company’s stock valued at $11,128,000 after buying an additional 303,461 shares during the last quarter. Opaleye Management Inc. acquired a new position in Checkpoint Therapeutics in the 1st quarter valued at $9,188,000. Geode Capital Management LLC grew its stake in Checkpoint Therapeutics by 25.0% in the 1st quarter. Geode Capital Management LLC now owns 798,553 shares of the company’s stock valued at $2,507,000 after buying an additional 159,785 shares during the last quarter. Spotlight Asset Group Inc. grew its stake in Checkpoint Therapeutics by 714.5% in the 1st quarter. Spotlight Asset Group Inc. now owns 651,597 shares of the company’s stock valued at $2,046,000 after buying an additional 571,597 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Checkpoint Therapeutics by 10.9% in the 4th quarter. Northern Trust Corp now owns 562,491 shares of the company’s stock valued at $1,491,000 after buying an additional 55,330 shares during the last quarter. Institutional investors own 20.26% of the company’s stock.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Read More: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.